O	0	10	Protective
O	11	18	effects
O	19	21	of
B-intervention	22	33	salidroside
O	34	36	on
B-condition	37	47	epirubicin
I-condition	47	48	-
I-condition	48	55	induced
I-condition	56	61	early
I-condition	62	66	left
I-condition	67	78	ventricular
I-condition	79	87	regional
I-condition	88	96	systolic
I-condition	97	108	dysfunction
O	109	111	in
O	112	120	patients
O	121	125	with
O	126	132	breast
O	133	139	cancer
O	139	140	.

O	141	152	Salidroside
O	153	154	[
O	154	155	2
O	155	156	-
O	156	157	(
O	157	158	4
O	158	159	-
O	159	172	hydroxyphenyl
O	172	173	)
O	173	178	ethyl
O	178	179	-
O	179	180	β
O	180	181	-
O	181	182	D
O	182	183	-
O	183	198	glucopyranoside
O	198	199	]
O	199	200	,
O	201	204	one
O	205	207	of
O	208	211	the
O	212	216	most
O	217	223	potent
O	224	235	ingredients
O	236	245	extracted
O	246	250	from
O	251	254	the
O	255	260	plant
O	261	269	Rhodiola
O	270	275	rosea
O	276	277	L
O	277	278	.
O	278	279	,
O	280	283	has
O	284	288	been
O	289	294	shown
O	295	297	to
O	298	302	have
O	303	304	a
O	305	319	cardiovascular
O	320	330	protective
O	331	337	effect
O	338	340	as
O	341	343	an
O	344	355	antioxidant
O	355	356	,
O	357	360	and
O	361	366	early
O	367	376	treatment
O	377	379	of
O	380	390	epirubicin
O	390	391	-
O	391	398	induced
O	399	413	cardiotoxicity
O	414	417	has
O	418	422	been
O	423	426	the
O	427	432	focus
O	433	435	of
O	436	444	clinical
O	445	457	chemotherapy
O	458	460	in
O	461	469	patients
O	470	474	with
O	475	481	breast
O	482	488	cancer
O	488	489	.

O	490	497	However
O	497	498	,
O	499	502	the
O	503	519	cardioprotective
O	520	527	effects
O	528	530	of
O	531	542	salidroside
O	543	545	on
O	546	556	epirubicin
O	556	557	-
O	557	564	induced
O	565	579	cardiotoxicity
O	579	580	,
O	581	591	especially
O	592	597	early
O	598	602	left
O	603	614	ventricular
O	615	623	regional
O	624	632	systolic
O	633	644	dysfunction
O	644	645	,
O	646	650	have
O	651	653	to
O	654	658	date
O	659	663	been
O	664	672	sparsely
O	673	685	investigated
O	685	686	.

O	687	690	The
O	691	694	aim
O	695	697	of
O	698	702	this
O	703	708	study
O	709	712	was
O	713	715	to
O	716	727	investigate
O	728	731	the
O	732	742	protective
O	743	750	effects
O	751	753	of
O	754	765	salidroside
O	766	768	in
O	769	779	preventing
O	780	785	early
O	786	790	left
O	791	802	ventricular
O	803	811	regional
O	812	820	systolic
O	821	832	dysfunction
O	833	840	induced
O	841	843	by
O	844	854	epirubicin
O	854	855	.

B-total-participants	856	861	Sixty
O	862	870	patients
O	871	875	with
O	876	890	histologically
O	891	900	confirmed
O	901	907	breast
O	908	914	cancer
O	915	919	were
O	920	928	enrolled
O	928	929	.

O	930	938	Eligible
O	939	947	patients
O	948	952	were
O	953	963	randomized
O	964	966	to
O	967	974	receive
O	975	986	salidroside
O	987	988	(
O	988	991	600
O	992	994	mg
O	994	995	/
O	995	998	day
O	998	999	;
O	1000	1001	n
O	1002	1003	=
B-intervention-participants	1004	1006	30
O	1006	1007	)
O	1008	1010	or
B-control	1011	1018	placebo
O	1019	1020	(
O	1020	1021	n
O	1022	1023	=
B-control-participants	1024	1026	30
O	1026	1027	)
O	1028	1036	starting
O	1037	1038	1
O	1039	1043	week
O	1044	1050	before
O	1051	1063	chemotherapy
O	1063	1064	.

O	1065	1073	Patients
O	1074	1078	were
O	1079	1091	investigated
O	1092	1094	by
O	1095	1100	means
O	1101	1103	of
O	1104	1120	echocardiography
O	1121	1124	and
O	1125	1131	strain
O	1132	1136	rate
O	1137	1138	(
O	1138	1140	SR
O	1140	1141	)
O	1142	1149	imaging
O	1149	1150	.

O	1151	1153	We
O	1154	1158	also
O	1159	1167	measured
O	1168	1174	plasma
O	1175	1189	concentrations
O	1190	1192	of
O	1193	1201	reactive
O	1202	1208	oxygen
O	1209	1216	species
O	1217	1218	(
O	1218	1221	ROS
O	1221	1222	)
O	1222	1223	.

O	1224	1227	All
O	1228	1238	parameters
O	1239	1243	were
O	1244	1252	assessed
O	1253	1255	at
O	1256	1264	baseline
O	1265	1268	and
O	1269	1270	7
O	1271	1275	days
O	1276	1281	after
O	1282	1286	each
O	1287	1290	new
O	1291	1301	epirubicin
O	1302	1306	dose
O	1307	1309	of
O	1310	1313	100
O	1314	1316	mg
O	1316	1317	/
O	1317	1319	m2
O	1319	1320	.

O	1321	1322	A
B-outcome	1323	1330	decline
I-outcome	1331	1333	of
I-outcome	1334	1337	the
I-outcome	1338	1340	SR
I-outcome	1341	1345	peak
O	1346	1349	was
O	1350	1358	observed
O	1359	1361	at
O	1362	1364	an
O	1365	1375	epirubicin
O	1376	1380	dose
O	1381	1383	of
O	1384	1387	200
O	1388	1390	mg
O	1390	1391	/
O	1391	1393	m2
O	1393	1394	,
O	1395	1399	with
O	1400	1402	no
O	1403	1414	significant
O	1415	1426	differences
O	1427	1434	between
O	1435	1446	salidroside
O	1447	1450	and
O	1451	1458	placebo
O	1459	1460	(
B-iv-cont-mean	1460	1461	1
I-iv-cont-mean	1461	1462	.
I-iv-cont-mean	1462	1464	35
O	1465	1466	±
B-iv-cont-sd	1467	1468	0
I-iv-cont-sd	1468	1469	.
I-iv-cont-sd	1469	1471	36
O	1472	1474	vs
B-cv-cont-mean	1475	1476	1
I-cv-cont-mean	1476	1477	.
I-cv-cont-mean	1477	1479	42
O	1480	1481	±
B-cv-cont-sd	1482	1483	0
I-cv-cont-sd	1483	1484	.
I-cv-cont-sd	1484	1486	49
I-cv-cont-sd	1486	1487	/
I-cv-cont-sd	1487	1493	second
O	1493	1494	)
O	1494	1495	.

O	1496	1498	At
O	1499	1506	growing
B-outcome	1507	1517	cumulative
I-outcome	1518	1523	doses
I-outcome	1524	1526	of
I-outcome	1527	1537	epirubicin
O	1537	1538	,
O	1539	1542	the
O	1543	1545	SR
O	1546	1556	normalized
O	1557	1561	only
O	1562	1566	with
O	1567	1578	salidroside
O	1578	1579	,
O	1580	1587	showing
O	1588	1589	a
O	1590	1601	significant
O	1602	1612	difference
O	1613	1615	in
O	1616	1626	comparison
O	1627	1631	with
O	1632	1639	placebo
O	1640	1642	at
O	1643	1653	epirubicin
O	1654	1659	doses
O	1660	1662	of
O	1663	1666	300
O	1667	1669	mg
O	1669	1670	/
O	1670	1672	m2
O	1673	1674	(
B-iv-cont-mean	1674	1675	1
I-iv-cont-mean	1675	1676	.
I-iv-cont-mean	1676	1678	67
O	1679	1680	±
B-iv-cont-sd	1681	1682	0
I-iv-cont-sd	1682	1683	.
I-iv-cont-sd	1683	1685	43
O	1686	1688	vs
B-cv-cont-mean	1689	1690	1
I-cv-cont-mean	1690	1691	.
I-cv-cont-mean	1691	1693	32
O	1694	1695	±
B-cv-cont-sd	1696	1697	0
I-cv-cont-sd	1697	1698	.
I-cv-cont-sd	1698	1700	53
I-cv-cont-sd	1700	1701	/
I-cv-cont-sd	1701	1707	second
O	1707	1708	,
O	1709	1710	p
O	1711	1712	<
O	1713	1714	0
O	1714	1715	.
O	1715	1717	05
O	1717	1718	)
O	1719	1722	and
O	1723	1726	400
O	1727	1729	mg
O	1729	1730	/
O	1730	1732	m2
O	1733	1734	(
B-iv-cont-mean	1734	1735	1
I-iv-cont-mean	1735	1736	.
I-iv-cont-mean	1736	1738	68
O	1739	1740	±
B-iv-cont-sd	1741	1742	0
I-iv-cont-sd	1742	1743	.
I-iv-cont-sd	1743	1745	29
O	1746	1748	vs
B-cv-cont-mean	1749	1750	1
I-cv-cont-mean	1750	1751	.
I-cv-cont-mean	1751	1753	40
O	1754	1755	±
B-cv-cont-sd	1756	1757	0
I-cv-cont-sd	1757	1758	.
I-cv-cont-sd	1758	1760	23
I-cv-cont-sd	1760	1761	/
I-cv-cont-sd	1761	1767	second
O	1767	1768	,
O	1769	1770	p
O	1771	1772	<
O	1773	1774	0
O	1774	1775	.
O	1775	1777	05
O	1777	1778	)
O	1778	1779	.

O	1780	1788	Moreover
O	1788	1789	,
O	1790	1791	a
O	1792	1803	significant
O	1804	1812	increase
O	1813	1815	in
B-outcome	1816	1822	plasma
I-outcome	1823	1837	concentrations
I-outcome	1838	1840	of
I-outcome	1841	1844	ROS
O	1845	1848	was
O	1849	1854	found
O	1855	1859	with
O	1860	1867	placebo
O	1867	1868	,
O	1869	1872	but
O	1873	1877	they
O	1878	1886	remained
O	1887	1896	unchanged
O	1897	1901	with
O	1902	1913	salidroside
O	1913	1914	.

O	1915	1926	Salidroside
O	1927	1930	can
O	1931	1938	provide
O	1939	1940	a
O	1941	1951	protective
O	1952	1958	effect
O	1959	1961	on
O	1962	1972	epirubicin
O	1972	1973	-
O	1973	1980	induced
O	1981	1986	early
O	1987	1991	left
O	1992	2003	ventricular
O	2004	2012	regional
O	2013	2021	systolic
O	2022	2033	dysfunction
O	2034	2036	in
O	2037	2045	patients
O	2046	2050	with
O	2051	2057	breast
O	2058	2064	cancer
O	2064	2065	.
